Mostrando entradas con la etiqueta Bladder. Mostrar todas las entradas
Mostrando entradas con la etiqueta Bladder. Mostrar todas las entradas

martes, 1 de mayo de 2012

Bladder cancer diagnosis encourages smokers to quit - Oncology Nurse Advisor

(HealthDay News) -- Smokers with a new diagnosis of bladder cancer are significantly more likely to quit compared with smokers in the general population, according to a study published online April 23 in the Journal of Clinical Oncology.

Jeffrey C. Bassett, M.D., M.P.H., from the University of California in Los Angeles, and colleagues investigated the impact of a bladder cancer diagnosis on patterns of tobacco use and smoking cessation in a random sample of noninvasive bladder cancer survivors diagnosed in 2006. A total of 344 respondents of 492 eligible participants completed a survey on tobacco use (70 percent response rate) and were compared by smoking status. To ascertain the impact of cancer diagnosis on tobacco use, respondents who smoked at diagnosis were compared with general population controls from the California Tobacco Survey.

The researchers found that 74 percent of respondents had a history of cigarette use, and 17 percent were smokers at the time of diagnosis. Smokers with a new diagnosis of bladder cancer were significantly more likely to quit (48 percent) than smokers in the general population (10 percent) (P < 0.001). The reasons most often cited for smoking cessation were bladder cancer diagnosis and advice of the urologist. When a urologist was the source of their understanding, respondents were more likely to endorse smoking as a risk factor for bladder cancer.

"Given the negative impact that continued smoking has on recurrence, progression, morbidity, and mortality, each diagnosis of bladder cancer in a smoker should be viewed as an opportunity to help them quit their tobacco use for good," the authors conclude.

Abstract
Full Text (subscription or payment may be required)


View the original article here

Canada Adds Warning for Actos Bladder Cancer as U.S. Actos Lawsuits Mount - Albany Times Union

The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com

(PRWEB) April 27, 2012

The Actos Resource Center, a consumer advocacy group, is alerting patients in the United States of an additional warning issued over the safety of Actos by Canada’s top drug regulatory agency.

Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder cancer. Authorities there also stated they had come to an agreement with Takeda Pharmaceuticals, maker of the drug, to add a label warning addressing the risk.

The Canadian agency functions in much the same way as the FDA in the United States, who issued a similar warning associating Actos with bladder cancer on June 15, 2011.

According to The Canadian Press on April 19, 2012, the latest warning was issued in response to a study by Health Canada which was commenced last June, finding users of Actos are more than 40% more likely to develop bladder cancer.

The news is the latest in a string of warnings over Actos. Last year, CBS News reported on June 10, 2011 that Germany and France had banned Actos prescriptions after a study by the French Medicines Agency indicated long-term use could increase bladder cancer occurrences by as much as 40 percent.

In the United States, Takeda faces growing litigation concerns. Bloomberg reported on March 13, 2012 that as many as 10,000 patients may eventually file an Actos bladder cancer lawsuit. In December, a federal Judicial Panel on Multidistrict Litigation issued an order consolidating all lawsuits to a federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).

The Actos Resource Center urges anyone who has taken Actos to monitor for bladder cancer symptoms, and anyone who has been affected by bladder cancer to learn about their legal options.

The Actos Bladder Cancer Center only works with qualified Actos lawyers named to the Actos Plaintiff Steering Committee leading this litigation.

For more information on the research, warnings, side effects and legal news pertaining to the drug Actos, or for a recommendation of the top Actos lawyers, visit ActosCancer.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactos/bladder-cancer/prweb9437804.htm


View the original article here

Canada Adds Warning for Actos Bladder Cancer as U.S. Actos Lawsuits Mount - Virtual-Strategy Magazine

 The Actos Resource Center is the Web’s largest source for information on Actos research, side effects and legal news. Visit http://www.ActosCancer.com(PRWEB) April 27, 2012


The Actos Resource Center, a consumer advocacy group, is alerting patients in the United States of an additional warning issued over the safety of Actos by Canada’s top drug regulatory agency.


Health Canada issued a warning on April 19, 2012 that the diabetes drug Actos may cause an increased risk of bladder cancer. Authorities there also stated they had come to an agreement with Takeda Pharmaceuticals, maker of the drug, to add a label warning addressing the risk.


The Canadian agency functions in much the same way as the FDA in the United States, who issued a similar warning associating Actos with bladder cancer on June 15, 2011.


According to The Canadian Press on April 19, 2012, the latest warning was issued in response to a study by Health Canada which was commenced last June, finding users of Actos are more than 40% more likely to develop bladder cancer.


The news is the latest in a string of warnings over Actos. Last year, CBS News reported on June 10, 2011 that Germany and France had banned Actos prescriptions after a study by the French Medicines Agency indicated long-term use could increase bladder cancer occurrences by as much as 40 percent.


In the United States, Takeda faces growing litigation concerns. Bloomberg reported on March 13, 2012 that as many as 10,000 patients may eventually file an Actos bladder cancer lawsuit. In December, a federal Judicial Panel on Multidistrict Litigation issued an order consolidating all lawsuits to a federal court in Louisiana. The case is known as In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).


The Actos Resource Center urges anyone who has taken Actos to monitor for bladder cancer symptoms, and anyone who has been affected by bladder cancer to learn about their legal options.


The Actos Bladder Cancer Center only works with qualified Actos lawyers named to the Actos Plaintiff Steering Committee leading this litigation.


For more information on the research, warnings, side effects and legal news pertaining to the drug Actos, or for a recommendation of the top Actos lawyers, visit ActosCancer.com.


For the original version on PRWeb visit: http://www.prweb.com/releases/prwebactos/bladder-cancer/prweb9437804.htm 


View the original article here

lunes, 30 de abril de 2012

Diabetes drug may pose bladder cancer risk: Health Canada - CTV.ca

Diabetes drug may pose bladder cancer risk: Health Canada




TORONTO — Taking the diabetes drug Actos may increase one's risk of developing bladder cancer, Health Canada and the drug's maker, Takeda Canada Inc., said in a warning issued Thursday.


The statement was the culmination of a safety assessment Health Canada announced last June, two days after the U.S. Food and Drug administration issued a warning similar to the one the Canadian drug regulator just announced.


Health Canada said the drug's labelling will be changed to reflect the potential risk.


Actos is the brand name for pioglitazone, a drug from the glitazone family used for the treatment of Type 2 diabetes. It is a sister drug to Avandia, a once widely used diabetes drug that fell out of favour after studies found it increased users' risk of heart disease.


While it was thought that Actos was safer than Avandia -- at least in terms of heart disease -- there have been suggestions for awhile that using the drug, especially long-term, might increase one's risk of developing bladder cancer.


Takeda is conducting a 10-year study trying to see if the link is real. Data from the midway point of the study points to the possibility that it is, Health Canada said in its statement.


Dr. Muhammad Mamdani, director of the Applied Health Research Centre of the Li Ka Shing Knowledge Institute at Toronto's St. Michael's Hospital, said the warning likely won't impact that many people, because doctors have been moving their patients off the drug over the past few years.


In fact, in Ontario Actos is no longer on the list of drugs that doctors can freely prescribe; it has been moved to the "exceptional access" list and can only be prescribed with approval, Mamdani said.


Dr. David Juurlink, head of the division of clinical pharmacology at the University of Toronto, said at this point there is little need to resort to this drug, unless a patient has done extraordinarily well on it in the past.


"I personally would not be comfortable using it as a long-term therapy because bladder cancer is ... not something that's reversible. It's not a skin rash that goes away when you stop the drug," said Juurlink, who actively campaigned to get Avandia out of use.


"We've got other options. And when you've got other options why would you take an option that has some well-established side-effects and some side-effects that are less well established but ones that you would for sure rather avoid?"


Juurlink suggested that anyone taking the drug who has concerns about this news should speak to their doctor.


The Health Canada statement noted that in the Takeda trial, people who weren't using the drug developed bladder cancer at a rate of about seven cases in every 10,000 people. But there were 10 cases per 10,000 people among the people using Actos for control of Type 2 diabetes.


The statement says the risk appears to be highest for people who took the drug for the longest duration or at the highest dosages, but it isn't possible to rule out a risk even after short-term use.


The drug regulator suggests that Actos should not be used to treat patients with active bladder cancer, a history of bladder cancer or uninvestigated blood in their urine.


It also suggested doctors should assess a patient's risk for bladder cancer before starting treatment with this drug. Known risk factors include age, smoking, a family history of bladder cancer, exposure to chemicals in the workplace, certain cancer treatments and radiation therapy.


Share with your social Network:


View the original article here

Neoadjuvant Chemotherapy Urged for Rare Type of Bladder Cancer - Renal and Urology News

Neoadjuvant chemotherapy for patients with small cell urothelial carcinoma (SCUC) improves their likelihood of survival compared with a historical cohort of patients treated with initial cystectomy, a study found.

Based on the study's findings, researchers concluded that neoadjuvant chemotherapy should be considered for all patients with surgically resectable SCUC.

Investigators at the M.D. Anderson Cancer Center in Houston led by Arlene Siefker-Radtke, MD, studied 95 SCUC patients who were surgical candidates. Of these, 48 received neoadjuvant chemotherapy and 47 underwent initial surgery. The median overall and disease-specific survival were significantly greater in the adjuvant chemotherapy recipients than those who had initial surgery (159.5 vs. 18.3 months and 79% vs. 20%, respectively), according to a report in European Urology (published online ahead of print).

Adjuvant chemotherapy had no impact on overall survival among patients treated with initial cystectomy, although the small number of patients limits the impact of this finding. The median overall survival for those treated and not treated with adjuvant chemotherapy was 18.1 vs. 18.3 months, respectively.

“Neoadjuvant chemotherapy for SCUC is associated with a high rate of pathologic downstaging and correlates significantly with higher survival as compare to historical expectations,” the authors wrote. “With initial surgery, there is an increased risk of pathologic upstaging, at times leading to an aborted cystectomy and resulting in poor outcomes.”

Neoadjuvant chemotherapy resulted in pathologic downstaging in 62% of tumors compared with only 9% for those who underwent initial surgery.

View the original article here

Spectrum says bladder cancer drug fails, buys Allos - Reuters

(Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) said its experimental drug to treat a common form of bladder cancer failed to significantly reduce the recurrence of tumors in late-stage trials, sending its shares down 14 percent.


Separately, the biotechnology company said it agreed to buy Allos Therapeutics (ALTH.O) for about $206 million to gain access to its anti-cancer drug Folotyn.


Spectrum was testing the drug apaziquone in two late-stage trials for non-muscle invasive bladder tumors (NMIBC), which are currently removed through surgery.


NMIBC is a form of bladder cancer localized in the surface layers of the bladder. About 70 percent of all patients diagnosed with bladder cancer have NMIBC.


Patients in the late-stage trials either received a single dose of apaziquone or a placebo into the bladder after the surgery.


Spectrum, which is developing the drug with medical device maker Allergan Inc (AGN.N), said the drug failed to show a statistically significant difference in the rate of tumor recurrence at two years against a placebo.


The company, however, said the pooled data from both studies showed a statistically significant treatment effect.


Spectrum said it plans to meet the U.S. Food and Drug Administration to discuss further steps.


"It is unusual for the FDA to review the NDA (new drug application) with the pooled data, but it is possible," said MLV & Co analyst George Zavoico.


Zavoico said in an email that MLV expects to receive or intends to seek compensation for investment banking services from Spectrum in the next three months.


DEAL TERMS


Allos shareholders will get $1.82 in cash for each share, which represents a premium of 27 percent to Allos' Wednesday close, plus a contingent value right that gives shareholders 11 cents, if certain regulatory and sales milestones are met in Europe.


Allos' lead drug Folotyn, which is used to treat relapsed or refractory peripheral T-cell lymphoma, raked in sales of about $50 million last year. The drug had been rejected by an European advisory committee and the company had submitted a request to re-examine its application.


The committee is expected to issue its decision in the second quarter of this year.


On a conference call with analysts, Spectrum's Chief Executive Rajesh Shrotriya said Folotyn annual sales could cross $100 million.


MLV's Zavoico said the drug could reach $100 million sales, especially if they get European approval.


Spectrum, which also makes lymphoma drug Zevalin, expects the deal to save about $40 million to $50 million in 2013.


"Folotyn is prescribed by the same physicians who prescribe Zevalin," said Shrotriya. A salesman selling two products would bring down expenses.


Last year, AMAG Pharmaceuticals Inc (AMAG.O) had dropped its plan to buy Allos after AMAG shareholders opposed the deal.


Spectrum expects to close the deal in the second quarter and add to its fourth-quarter earnings. The company expects to finance the acquisition with a combination of cash on hand and a revolving credit line from Bank of America.


Spectrum is advised by RBC Capital Markets and Allos by J.P. Morgan Securities.


Spectrum shares were down 10 percent at $11.03 in morning trade on Nasdaq, while Allos rose to $1.82.


(Reporting by Anand Basu in Bangalore; Editing by Don Sebastian)


View the original article here

lunes, 19 de marzo de 2012

Takeda Hid Actos Bladder Cancer Risks, Whistleblower Case Says - Salient News

The U.S. District Judge F. Dennis Saylor issued an order to unseal a whistleblower case by a former Takeda Pharmaceuticals medical reviewer involving the failure to report bladder cancer and Congestive Heart Failure (CHF) adverse events for the diabetes drug Actos.


The whistleblower is Dr. Helen Ge, a medical doctor and former safety consultant to Takeda’s pharmacovigilance division. Dr. Ge worked to review adverse events and to identify and evaluate potential safety signals for the diabetes drug Actos, the only drug in the same class and competing with GlaxoSmithKline’s Avandia.


Dr. Ge had direct knowledge of the Actos bladder cancer risk and, according to the complaint, encountered resistance from her superiors when she tried to report bladder cancer as related to Actos. Takeda’s adverse event database for Actos held more than 100 bladder cancers reported to the company, but only 72 reported to the FDA, which Dr. Ge referred to as “a serious discrepancy.” Takeda, like other drug companies, is required to update the U.S. Food and Drug Administration’s Adverse Event Reporting System.


Takeda Pharmaceutical Co. failed to give accurate reports to regulators about hundreds of congestive heart failure cases associated with its diabetes drug Actos, Dr. Ge claimed in a lawsuit. Additionally, the company failed to classify “non-hospitalized or non- fatal” congestive heart failure cases as serious from late 2007 to January 2010, and supervisors directed the whistleblower to change her “related” assessment to unrelated.


According to her complain, Dr. Ge complained to her superiors that her medical assessments were being downgraded from “serious” to “non-serious” and that, as a result of this, the Congestive Heart Failure events were being under-reported to the FDA. As a result of her complaint, her contract with Takeda was terminated.


“Takeda’s motivation to fraudulently report and under-report the serious adverse events was driven by an economic desire to falsely enhance Actos’s safety profile and to increase sales,” Ge said. Takeda wanted to push that Actos was safer than GlaxoSmithKline Plc (GSK)’s Avandia diabetes drug, and that the company downplayed data suggesting a link between Actos and bladder cancer, according to the complaint.


In 2007, the FDA ordered Takeda and Glaxo to place its strongest warning on the labeling of their drugs about the risk of congestive heart failure, a condition that occurs when the heart doesn’t adequately pump blood. Avandia has since has been severely restricted in the U.S. Ge sued under the False Claims Act in 2010, and the suit was recently unsealed. The Justice Department decided not to intervene in the suit, after reviewing the claim, but the plaintiff hopes that additional evidence will be enough to persuade federal regulators to take a second look.



Nina, owner of NinaRotz.com, is a freelance writer and blogger. Nina’s work has been published and linked on Associated Content, Yahoo! Shine, Yahoo! Voices, eHow, Live Strong, CNN, USA Today, The Wall Street Journal, as well as various online magazines and blogs.


Tags: Actos, actos adverse failure, actos bladder cancer risks, actos heart, Avandia, bladder cancer, bladder cancer risks, Congestive Heart Failure, effects, Takeda, takeda whistleblower

View the original article here

domingo, 18 de marzo de 2012

Putting the Brakes on Bladder Cancer - dailyRx

As with any malignancy, once bladder cancer starts to travel to other parts of the body, an individual's chances of outliving it are diminished. So, preventing that spread is a major objective of research.


A protein that's sort of like a siren - versican - has been shown to help cancer cells get set up in the lung. This research discovered that another protein - RhoGD12 - silences versican so that cancer cells can't grow and thrive in the lung.

If your urine turns dark or rust colored, see your doctor.

The paper's senior author, Dan Theodorescu, M.D., Ph.D., director of the University of Colorado Cancer Center, says this finding could help people with bladder cancer live longer.


Metastasis isn't something that happens all of a sudden. Cells don't start moving just out of the blue.


No, these cells may have been stalking around in the blood or lymph for a while, just looking for a place to land, latch on and grow. 


The lungs are a great landing pad for cancer cells.


But getting settled in is stressful for these cells. They get overwhelmed and panicked. When that happens, they make a distress call, and versican responds to save the day and the cancer.


The more versican that builds up, the more support troops arrive in what's known as macrophages, which are sort of like garbage men. They eat up stuff that could a cell harm, even if that cell is a potential killer.


So the macrophages support the bladder cancer cells in getting set up in lungs and that's when metastasis takes hold and over.


The protein RhoGDI2 puts the brakes on this process, Dr. Theodorescu and colleagues demonstrated, by decreasing the levels of versican. When they added RhoGD12 to a bladder tumor in the lab, versican and metastasis were both decreased. 


"We believe this study provides an important contribution to the scientific literature by delineating for the first time a new mechanism of metastasis suppression, namely that suppression of metastasis is possible by altering the tumor microenvironment, including reducing the presence of macrophages," Theodorescu says.


The story doesn't end there. Another protein called CCL2 helps versican recruit macrophages. And that's a nifty finding because, clinical trials are already under way testing drugs that inhibit, or block CCL2.


If the laboratory results can be repeated in humans, these drugs might just be the ticket to lowering metastasis, thereby significantly extending lives.


When asked what all this means, Dr. Theodorescu told dailyRx, “The significance of our study to patients is that two of the drugs used have the very real possibility of crossing over quickly to human use. This could be a major advance in keeping bladder cancer from metastasizing to the lungs,” he concluded.


This study was published March 12, 2012 in the Journal of Clinical Investigation. 


The research was funded by the National Institutes of Health. No conflicts of interest were disclosed.

Bladder Cancer

Bladder cancer is the fourth most common type of cancer in the United States, and over 64,000 men and women are diagnosed each year, with men making up four out of every five diagnoses. The most common type is called transitional cell carcinoma, which causes abnormal growth of cells on the inner lining of the urinary bladder.


Risk for developing bladder cancer is primarily due to environmental exposures. Cigarette smoking is the most serious risk factor, responsible for up to half of bladder cancer in men, and a third in women.

 function moreOrLess(obj){if(jQuery(obj).hasClass('condition_overview_more')){jQuery('#_more_hidden').css('display','');jQuery('#cov_more').css('display','none');jQuery('#cov_less').css('display','');} else {jQuery('#_more_hidden').css('display','none');jQuery('#cov_more').css('display','');jQuery('#cov_less').css('display','none');}}

Occupational exposure to chemicals is another serious risk factor, with bus drivers, rubber workers, motor mechanics, leather workers, blacksmiths, machine setters and mechanics being at particular risk. As with most cancers, exposure to radiation and chemotherapy also increase risk.


Symptoms of bladder cancer are non-specific and may resemble those of conditions like bladder and prostate infections. Most people notice blood in the urine, painful urination, and urinary frequency and urgency. As cancer progresses, patients may notice general symptoms of advanced cancer such as weight loss, anemia, fatigue, and abdominal pain.


Diagnosis is primarily made by cystoscopy, where a camera is inserted through the urethra to visualize and biopsy the inside of the bladder. Examination of the urine may reveal cancerous cells as well.


Early stage bladder cancer can be treated with bladder-sparing surgery to remove the tumor, as well as treat chemotherapy directly into the bladder (Doxorubicin (Adriamycin), Mitomycin-C (Mutamycin), Thiotepa (Thioplex) and immunotherapy for the bladder (Bacillus Calmette-Guérin therapy, a mycobacterium that prevents cancer recurrence). Later stage cancers where the tumor has advanced into the muscle tissue of the bladder have much lower survival rates. Removal of the entire bladder )as well as prostate and seminal vesicles in men, and urethra, uterus, and the front wall of the vagina in women) may be necessary, as well as systemic chemotherapy (gemcitabine/cisplatin, Paclitaxel/carboplatin).


Fruit and yellow-orange vegetables, particularly carrots and selenium are associated with a moderately reduced risk of bladder cancer. Citrus fruits and cruciferous vegetables were also identified as having a possible protective effects.

 Related Topics: Bladder CancerNews Share / Bookmark this Story Facebook FacebookTwitter TwitterGoogle GoogleYahoo YahooDigg Diggdel.icio.us del.icio.usStumbleUpon StumbleUponLinkedIn LinkedInGoogle Buzz Google BuzzSlashDot SlashDotNewsvine NewsvineFavorite Favorite Review Reviewed by: Joseph V. Madia, MD Review Date:  Wednesday March 14, 2012Last Updated: Thursday March 15, 2012Citation: University of Colorado Denver, "Major study stops bladder cancer from metastasizing to lungs" 1-800-TKO-Cancer Source: dailyRx top nav menuHomeConditionsAllergiesArthritisAsthmaCardiovascularCancerConcussionsEmphysemaEye DiseasesGastrointestinal DisordersDiabetes - Type 1Diabetes - Type 2 Heart AttackImmunizationsInfectious DiseasesKidney DiseasesKidney FailureMen's HealthNeuromuscular DiseasesObesityOBGYNPatient-Safety & EducationPediatricsRheumatoid ArthritisSclerodermaTraumaWomen's HealthMedicationsClinical TrialsFDA AlertsFDA ApprovalsNatural MedicineOTC NewsPrescription Drug NewsMental HealthAddictionsAlcohol AddictionAlzheimersAnorexiaAnxiety DisordersAttention Deficit Disorder (ADD)AutismAttention Deficit Hyperactivity Disorder (ADHDBi-PolarBorderline Personality DisorderDementiaDepressionDrug AddictionEating DisordersFood AddictionGeneralized Anxiety Disorder (GAD)Obsessive Compulsive Disorder (OCD)Panic DisorderPost Traumatic Stress Disorder (PTSD)SchizophreniaSex AddictionSocial Anxiety Disorder (SAD)Sleep DisordersStressSuicide PreventionTobacco AddictionSharedailyRx NewsletterdailyRx PrescribedailyRx on your site (feeds) SearchSearch this site: ConditionsAAcid RefluxAddictionsAdenocarcinomaAlcohol AddictionAllergiesAlzheimer's DiseaseAmyotrophic Lateral SclerosisAnemiaAnkylosing SpondylitisAnorexia NervosaAnxiety DisordersAortic AneurysmAsthmaAtherosclerosisAtrial FibrillationAttention Deficit Disorder (ADD)Attention Deficit Hyperactivity Disorder (ADHD)Autism Spectrum DisordersBBack PainBarrett's EsophagusBasal Cell CarcinomaBinge-Eating DisorderBipolar DisorderBladder CancerBleeding/Clotting DisordersBlindness/Macular DegenerationBlood CancerBone CancerBorderline Personality DisorderBrain CancerBreast Cancer (female)Breast Cancer (male)Bulimia NervosaCCancerCardiovascularCataractsCeliac DiseaseCervical CancerChild DisordersChronic Obstructive Pulmonary DiseaseChronic Pain ConditionsCirrhosisColon CancerConcussionCongestive Heart FailureConstipationCrohn's DiseaseCystic FibrosisDDeafness/Hearing LossDeep Venous ThrombosisDementiaDental HealthDepressionDermatologyDiabetesDiabetic RetinopathyDialysisDiarrheaDrug AddictionEEating DisordersEczemaEmotional HealthEmphysemaEnd Stage Renal DiseaseEpilepsy/Seizure DisordersErectile DysfunctionEsophageal CancerEye DiseaseFFamily PlanningFemale CancerFibromyalgiaFibrotic DiseaseFood AddictionFood Borne IllnessGGall Bladder CancerGallstonesGastrointestinalGeneralized Anxiety Disorder (GAD)GlaucomaGoutGraves' DiseaseHHealthy DevelopmentHealthy Eating And DietHealthy HomeHeart AttackHematologyHemophiliaHepatitisHiatal HerniaHigh CholesterolHIV/AIDSHuntington's DiseaseHypertensionHyperthyroidismHypothyroidismIImmune Mediated AnemiaImmunizationsIncontinence Indoor AllergiesInfectious DiseaseInfluenzaIron Deficiency AnemiaIrritable Bowel SyndromeJJoint ReplacementKKidney CancerKidney DiseaseKidney FailureLLactose Intolerance/Food AllergyLambert-Eaton SyndromeLeukemiaLiposarcomaLiver CancerLiver DiseaseLow TestosteroneLung CancerLupusLymphomaMMad Cow DiseaseMale CancerMelanomaMen's HealthMeningitis/EncephalitisMenopause/Hormone ReplacementMental HealthMetabolic DefectsMigraine/HeadachesMultiple MyelomaMultiple SclerosisMuscle/Soft Tissue CancerMuscular DystrophyMyosarcomaNNasal CancerNervous SystemNeuromuscular DiseaseNon-Small CellOObesityObsessive Compulsive Disorder (OCD)Obstetrics/GynecologyOral CancerOsteoarthritisOsteoporosisOvarian CancerOveractive Bladder OABPPancreatic CancerPancreatitisPanic DisorderParkinson's DiseasePatient Safety/EducationPediatricsPeripheral Arterial Disease (PAD)PneumoniaPolycythemiaPost-Traumatic Stress Disorder (PTSD)Prenatal CareProstate CancerPsoriasisPsoriatic ArthritisPulmonaryPulmonary DiseasePulmonary EmbolismRRectal CancerRenal HypertensionRheumatic DiseaseRheumatoid ArthritisRosaceaSSchizophreniaSclerodermaSeasonal AllergiesSex AddictionSexual HealthSexually Transmitted DiseaseSickle Cell AnemiaSjogren's SyndromeSkin CancerSleep Apnea/InsomniaSleep DisordersSmall CellSmoking CessationSocial Anxiety Disorder (SAD)Squamous CellSquamous Cell CarcinomaStomach CancerStrep Throat/Rheumatic FeverStressStrokeSuicide PreventionTTesticular CancerThrombophiliaThyroid CancerThyroid DisordersTobacco AddictionTraumaTraumatic Brain InjuryTuberculosisType 1 DiabetesType 2 DiabetesUUlcerUlcerative ColitisUrinary Tract InfectionUterine CancerVVertigo/Balance DisordersViolence PreventionVon Willebrand DiseaseVulvar CancerWWomen's HealthA